New prostate cancer treatment reduces disease spread risk
Adding darolutamide to standard care reduced aggressive prostate cancer spread risk in a global phase 3 trial.
Dr Tamim Niazi noted these findings could influence care standards for individuals facing very high danger from the illness significantly. He stated longer-term data support offers meaningful opportunities to extend time without disease progression for many.
Prostate cancer remains the most frequently detected malignancy in Canadian males with an estimated 29300 new cases expected in 2026 alone. Approximately 5300 deaths are anticipated this year according to current medical estimates and projections.
Researchers tested adding darolutamide to standard androgen deprivation therapy to help high-risk individuals avoid disease return. The double-blind study included 1106 patients from six nations including Canada, marking it as a major global effort.
Participants receiving the drug went longer without tumor expansion than those who received a placebo during the study period. Researchers also noted lower death rates and fewer increases in PSA levels which often signal the disease has returned.
“If supported by longer-term data, this approach offers a meaningful opportunity to extend the time patients live without cancer progression.”